Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Legionella Learnings: What the NY Outbreak Signals About a Growing National Vulnerability
The August 2025 New York Legionella outbreak was linked to contaminated cooling‑tower water across multiple buildings, exposing systemic infrastructure flaws. Traditional laboratory culturing can take up to ten days, allowing the bacteria to proliferate and spread. New rapid on‑site testing technologies deliver results in roughly 25 minutes and detect both culturable and viable‑but‑non‑culturable strains. Experts urge dynamic water‑management plans and continuous operator training to curb the growing national vulnerability.
Insulin Resistance Is Not a Disease: A Metabolic Reframe
Type 2 diabetes is reframed as chronic elevated blood sugar (CEBS) rather than a disease of insulin deficiency. The article argues that what is labeled "insulin resistance" is a protective cellular response to persistent glucose oversupply caused by excessive carbohydrate consumption....
A Remedy for Medicine Procurement: How Brazil Is Improving Decision-Making in a $75 Billion Market Using Open Data and AI
Brazil spends roughly US$75 billion annually on medicines through its universal health system, but fragmented procurement across 5,000 municipalities creates price volatility and opaque documentation. A coalition of government agencies and civil‑society groups launched the Medicamentos Transparentes platform, which consolidates purchase...
FDA Clears PCR Test that Detects 11 Gastrointestinal Pathogens
The FDA has cleared Cepheid’s Xpert GI Panel, a multiplex PCR test that identifies 11 gastrointestinal pathogens—including eight bacteria, two parasites and one virus—from a single stool sample. Results are available in just over an hour, dramatically faster than traditional culture...
Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
The FDA’s Center for Drug Evaluation and Research has launched the Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D) initiative under its Accelerating Rare disease Cures (ARC) program. LEADER 3D provides a suite of educational videos, downloadable...
How $50 Billion Can Help Transform Rural Healthcare
CMS has launched a $50 billion Rural Health Transformation Program aimed at overhauling care delivery in underserved areas. Founder Michael Dalton of Ovatient argues the initiative will only succeed if the funding fuels new value‑based, virtual‑first models that leverage telehealth and...
Antibacterial Effects of Crude Extracts From Tithonia Diversifolia and Solanum Torvum on Selected Shigella Species Demonstrated In Vitro
Researchers evaluated crude extracts from the African weed Tithonia diversifolia and the nightshade Solanum torvum for antibacterial activity against several Shigella strains. In vitro assays demonstrated clear zones of inhibition, with minimum inhibitory concentrations between 125 µg/mL and 250 µg/mL. Both extracts...
Beyond Vitals Spot Checks: Sibel Health and LookDeep Health Combine Wearable Monitoring with Real-Time Bedside AI
Sibel Health and LookDeep Health announced a strategic partnership that merges Sibel’s FDA‑cleared ANNE® One wearable, which continuously captures clinical‑grade vitals, with LookDeep’s aimee™ bedside AI that adds real‑time visual and audio context. The combined platform targets emergency departments, general...
Engineered Nanoplatform with Dual Anti‐Inflammatory and Microbiota‐Modulating Actions for Targeted Therapy in Chronic Inflammatory Bowel Disease
The study introduces BG/SOD@ZIF‑zc, a multifunctional nanoplatform that encapsulates superoxide dismutase within a copper‑doped ZIF framework and coats it with bacterial ghosts for targeted delivery to the colon. The formulation retains SOD activity in the harsh gastrointestinal tract, efficiently scavenges...
From Glucose to Vascular Health: The Future of Diabetes Care
Diabetes prevalence has surged past 800 million adults, with youth type 2 rates climbing 94 % since 1990, intensifying vascular complications like peripheral artery disease. Surveys reveal 55 % of Americans delay seeking care for leg pain and 80 % of primary‑care clinicians lack confidence...
Male Infertility Care to Shift Treatment Burden From Women
Infertility has long been framed as a women's issue, yet about half of cases stem from male factors. New treatments such as Igyxos' IGX12 monoclonal antibody, which enhances follicle‑stimulating hormone activity, aim to improve sperm production and reduce the physical...
Millions Are Overdue For Colon Cancer Screening
The death of 48‑year‑old actor James Van Der Beek underscores a surge in colorectal cancer among adults under 50, prompting the U.S. Preventive Services Task Force to lower the screening start age to 45 in 2021. A 2024 report estimates that roughly...
Fasting Insulin: The Overlooked Test Predicting Disease
The Most Important Blood Test Your Doctor Doesn't Order You can have normal blood sugar, normal A1C, and normal cholesterol… and still be metabolically sick. In this episode, Dr. Robert Lufkin explains why fasting insulin may be the single most important blood...
Division of Applied Regulatory Science
The Division of Applied Regulatory Science (DARS) operates within the FDA’s Office of Clinical Pharmacology and the Office of Translational Sciences. Its mandate is to translate emerging scientific advances into the agency’s regulatory framework, tackling complex questions that hinder drug...
Valo Health CEO: We Don’t Want Investors To Drive the Science
Valo Health is reshaping drug development by applying AI to human causal biology, aiming to raise clinical success rates from roughly 10% to 20%. The company leverages over 17 million de‑identified patient records and Mendelian randomization to pinpoint genetically validated targets....
When Innovation Gets Stuck: Humanity at the Core
A Parallels survey of 600+ global IT leaders found 94% fear vendor lock‑in, especially in health systems where platforms now underpin clinical, security and data functions. The study shows a shift from cost‑avoidance to protecting organisational freedom, prompting hybrid and...
Novo Nordisk Inks A $2.1 Billion Deal To Develop Next Generation Obesity Pills
Novo Nordisk has struck a deal with Boston biotech Vivtex worth up to $2.1 billion to develop next‑generation oral GLP‑1 obesity and diabetes pills. The partnership leverages Vivtex’s AI‑driven gastrointestinal‑on‑a‑chip platform that can boost drug absorption by orders of magnitude. Novo...
China’s Biopharma Advance Draws Financial Investment
Chinese biotech firms are moving beyond licensing deals as capital markets open, highlighted by a 64% rise in the Hang Seng Biotech Index in 2025. Reforms to listing rules since 2018 have unlocked public financing, enabling a record $138 billion in...
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
A patient in MacroGenics' Phase 2 LINNET trial of the bispecific antibody lorigerlimab suffered grade 4 neutropenia and septic shock, leading to a fatality and prompting the FDA to place a partial clinical hold on the study. The company also reported three...
Digital Health Rewired 2026 Programme Published
The Digital Health Rewired 2026 conference programme, featuring ten themed stages, has been released. More than 300 senior health‑IT leaders, including NHS CEOs, CIOs, CCIOs and CNIOs, will present sessions on digital transformation, cyber security, AI, and electronic patient records....
Proven Ways UKG Pro WFM Can Improve Healthcare Scheduling
UKG Pro Workforce Management (WFM) offers a structured, data‑driven approach to healthcare scheduling, tackling the sector’s chronic staffing volatility. By enabling early offers of open shifts through advanced scheduling, organizations can pre‑empt gaps, lower overtime, and align skill sets with patient...
Tooth Whitening without Enamel Damage? Vibration-Activated Powder Protects Pearly Whites for Better Oral Health
Researchers at Shanghai Xuhui District Stomatological Hospital and the Chinese Academy of Sciences have engineered a vibration‑activated teeth‑whitening powder (BSCT) that works with electric toothbrushes. The ceramic powder uses piezoelectric catalysis to generate reactive oxygen species for stain removal while...
How This Startup Is Showing that Voice-First AI Can Scale in Clinical Care for Root Cause Analysis
O-Health, an 18‑month‑old clinical AI startup, has built a voice‑first operating system that turns doctor‑patient conversations into structured clinical intelligence in real time. The platform runs on an edge‑first, sovereign AI stack with in‑house medical ASR and small language models,...
Translating Single-Cell Research Into Routine Preventive Screenings
Researchers are exploring single‑cell omics as a next‑generation tool for preventive health screening. By profiling thousands of individual cells, the technology can detect subtle genetic mutations and immune‑cell shifts years before clinical symptoms appear. Early studies have identified driver mutations...
Healthcare AI Shifting From Pilot to Profit, Report Finds
NVIDIA’s second State of AI in Healthcare report shows AI moving from experimentation to profit across radiology, drug discovery, medical devices and digital twins. Seventy percent of respondents now actively use AI, up from 63% a year earlier, and 69%...
COVID-19: Federal Efforts to Support Behavioral Health Programs During the Pandemic
The Substance Abuse and Mental Health Services Administration (SAMHSA) led a massive federal response to keep behavioral health services operational during COVID‑19, awarding over $32 billion in grants from FY2020‑2023, including $8.3 billion in pandemic‑specific funding. SAMHRA provided grant extensions, telehealth prescribing...
Zifo and Maze Therapeutics Partner to Power Precision Medicine
Zifo and Maze Therapeutics have teamed up to launch an AI‑powered platform that manages, stores, and scales massive biobank datasets. The solution tackles the fragmentation of genetic, proteomic, and phenotypic data by providing a unified workflow that delivers summary statistics...
2026’s Top 100 Digital Health & AI Innovators Unveiled
I’m proud to introduce 𝐓𝐡𝐞 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐅𝐮𝐭𝐮𝐫𝐢𝐬𝐭’𝐬 𝟏𝟎𝟎 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 𝐚𝐧𝐝 𝐀𝐈 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐨𝐟 𝟐𝟎𝟐𝟔! The digital health and AI fields are saturated with hype, and distinguishing the promising players from the noise is a challenge. The annual list is our...
New Guidelines Define Prior Therapy Lines in Multiple Myeloma
Guidelines for determination of the number of prior lines of therapy in multiple myeloma [Aug 13, 2015] @VincentRK , Richardson, San Miguel @BloodJournal https://t.co/Tdmr2gTUi6 #mmsm #ctsm #ClinicalTrials https://t.co/ZOobout75Q
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
Eli Lilly’s obesity drug Zepbound achieved a 25.5% weight loss in a head‑to‑head Phase 3 trial, outpacing Novo Nordisk’s CagriSema and sending Novo’s shares down 20%. The FDA launched Rare Disease Week, issuing draft guidance for a new Plausible Mechanism Pathway that...
PI‑Rd Triplets Show Superior Efficacy And
Comparative Effectiveness and Safety of PI-Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT-MM Data Analysis [Jan 13, 2026] @NoemiPuigM et al. European Journal of Haematology https://t.co/Vf7USecLlR #NCT02761187 #mmsm #openaccess https://t.co/C5Ya6TTQfo
Combining EMR and Multi‑omics Sharpens Biological Age Predictions
Assessment of biological age integrating electronic medical records and multi-omics increases accuracy for predicting outcomes @NatureAging https://t.co/7y60SSPTQf https://t.co/u02OlWMdQz
The Brain as the Rate-Limiting Organ for Longevity
The article argues that the brain is the rate‑limiting organ for longevity, asserting that neural network degradation drives functional decline across the body. While peripheral organ rejuvenation has advanced, preserving and repairing brain tissue remains the critical bottleneck. It proposes...
GSK's New CEO Targets Proven Science, Eyes Obesity Drugs
The FT's report on GSK's $950M deal to buy 35Pharma and its pulmonary arterial hypertension drug includes an interesting unnamed insider's quote that new CEO Luke Miels is going after assets where "the science is relatively settled." Maybe leaning into...
Circulating piRNAs May Predict Elderly Survival and Longevity
Strong claim that needs independent replication: "Our findings provide compelling evidence that circulating smRNAs—especially piRNAs—are powerful predictors of survival in older adults and potential biomarkers of longevity" https://t.co/oi4220zxGY https://t.co/yk3MX4VdQj
National Safety Council Launches SIF Prevention Tool that Clinical Laboratories Can Use
The National Safety Council introduced the Organization Safety Gap Analysis Tool, a digital assessment that translates its evidence‑based SIF Prevention Model for clinical laboratories. The ten‑to‑fifteen‑minute, color‑coded questionnaire evaluates seven core safety elements, from leadership to continuous improvement. By highlighting...
Novo's Vivtex Deal Could Unlock Superior Oral Obesity Meds
With Vivtex deal, Novo gains a chance at better oral obesity drugs https://t.co/DhIelbC9jI by @gwendolynawu $NVO #obesity
Dr. Hotez Warns of America's Vaccination Crisis
Stand Up! with Pete Dominick: 1538 Dr Peter Hotez on the state of Vaccination in America. My latest with @PeteDominick https://t.co/LsuvmglNBx
FDA Enforcement on Copycat GLP-1's Could Reshape Retail Pharmacy Economics: Q&A with David Graziano
The FDA’s crackdown on non‑approved or “copycat” GLP‑1 drugs is expected to push patients toward FDA‑approved therapies, elevating the role of retail pharmacies as primary access points. GoodRx’s head of retail network, David Graziano, says the company’s cost‑plus pricing model...
Can AI Reduce Medical Errors?
The episode discusses the alarming rate of medical errors—estimated at 800,000 to a million deaths annually—and explores how AI can help reduce these mistakes. The host highlights personal experience using AI tools like OpenEvidence, GPT, and Gemini to obtain specialist-level...
SteinCares Forges Licensing Agreement with Shilpa Biologicals for Biosimilars Across Latin America
SteinCares has signed a strategic licensing agreement with Shilpa Biologicals to commercialize a biosimilar across Latin America. Under the deal, SteinCares receives exclusive rights to register, market and distribute the product throughout the region, while Shilpa Biologicals will complete development...
Stryker Unveils Synchfix EVT for Flexible Syndesmotic Ankle Fixation
Medical device maker Stryker has launched Synchfix EVT, a flexible syndesmotic fixation system designed to simplify ankle stabilization procedures. The all‑in‑one, single‑use device integrates suture tensioning handles and a low‑profile titanium medial implant, reducing procedural complexity for both adult and adolescent...
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy
Mevion Medical Systems announced that its S250‑FIT proton therapy system has received CE marking under EU MDR, allowing marketing and clinical use across the European Union. The compact, LINAC‑vault‑ready platform, already cleared by the U.S. FDA, fits into standard radiation...
Vico Therapeutics Initiates Patient Dosing for VO659 Phase I/IIa Trial
Vico Therapeutics has initiated patient dosing in an expanded European cohort for its Phase I/IIa VO659 trial, targeting Huntington's disease, spinocerebellar ataxia type 3 and type 1. The study employs a twice‑annual intrathecal regimen and will monitor safety, tolerability, pharmacodynamics and pharmacokinetics...
NorthX Biologics and Demeetra Collaborate on GMP Manufacturing and CLD
NorthX Biologics and Demeetra have formed a strategic alliance to provide an end‑to‑end solution that couples Demeetra’s CleanCut CHO cell line development platform with NorthX’s GMP manufacturing capabilities. The partnership leverages a high‑titre GS‑knockout CHO cell line that carries no...
Evolution Summit By Marcus Evans | May 7-8, 2026 | The Ritz-Carlton, Fort Lauderdale, Florida
The Evolution Summit, organized by Marcus Evans, will take place May 7‑8, 2026 at the Ritz‑Carlton in Fort Lauderdale. The invitation‑only event convenes senior clinical‑trial executives with innovative suppliers to discuss pressing challenges in clinical operations and drug development. Featured speakers include...
Labcorp Expands PathAI Pact to Roll Out Digital Pathology Platform in US
Labcorp announced an expanded partnership with PathAI to deploy the AISight Dx digital pathology platform across its U.S. anatomic pathology labs and hospital sites. The AI‑enabled software will allow pathologists to scan, annotate and diagnose slides digitally, aiming to cut turnaround...
Carea Launches Support Platform for Complex Fertility Treatment
Carea has introduced a new "Trying to Conceive: IVF/IUI" mode within its pregnancy and postnatal wellbeing app, offering a day‑to‑day support system for women undergoing fertility treatment. The feature includes a personalised medication tracker, video guides, reminders, and a visual...
Sleep Cycle and Carnegie Mellon to Explore Sleep Data to Detect Outbreaks
Sleep Cycle and Carnegie Mellon University's Delphi Group have launched a five‑year research collaboration to test whether privacy‑preserved sleep data—particularly nightly cough intensity captured by Sleep Cycle’s Cough Radar—can augment traditional respiratory disease surveillance. The partnership will share de‑identified data...
Healthcare Before Medicare: Creating Your Own Action Plan
Roger Whitney concludes his four-part series on pre‑Medicare health care by introducing the OODA Loop—observe, orient, decide, act—as a practical decision framework. He walks listeners through building a five‑year cash‑flow plan, estimating MAGI, and assessing ACA subsidy eligibility alongside COBRA...